This study indicates that the use of vidarabine to suppress only the activity of AC5, but not the entire β-AR signaling pathway, may be preferable to β-AR blockade therapy for the treatment of CVD associated with periodontal disease (Fig. 5). The gene discussed is ADCY5; the disease is periodontal disorder.